COVID-19 in Patients With Chronic Liver Diseases
(COLD Trial)
Recruiting in Palo Alto (17 mi)
+22 other locations
RD
Overseen byRenumathy Dhanasekaran, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Stanford University
No Placebo Group
Trial Summary
What is the purpose of this trial?
This study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.
Research Team
RD
Renumathy Dhanasekaran, MD
Principal Investigator
Stanford University
Eligibility Criteria
Inclusion Criteria
Confirmed diagnosis of COVID-19
Personal history of either
Chronic hepatitis C
See 6 more
Treatment Details
Interventions
- Prospective Chart Review (Other)
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Control GroupExperimental Treatment1 Intervention
COVID-19 patients without Chronic Liver Disease.
Group II: Chronic Liver Disease GroupExperimental Treatment1 Intervention
COVID-19 patients with Chronic Liver Disease.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Mount Sinai School of MedicineNew York, NY
Stanford UniversityStanford, CA
Rush University Medical CenterChicago, IL
UCSF FresnoFresno, CA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
Trials
2527
Patients Recruited
17,430,000+